Display options
Cite
Uccini S, Colarossi C, Scarpino S, et al. Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours. Br J Cancer. 2006;95(1):49-55doi: 10.1038/sj.bjc.6603212.
Uccini, S., Colarossi, C., Scarpino, S., Boldrini, R., Natali, P. G., Nicotra, M. R., Perla, F. M., Mannarino, O., Altavista, P., Boglino, C., Cappelli, C. A., Cozzi, D., Donfrancesco, A., Kokai, G., Losty, P. D., McDowell, H. P., & Dominici, C. (2006). Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours. British journal of cancer, 95(1), 49-55. https://doi.org/10.1038/sj.bjc.6603212
Uccini, S, et al. "Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours." British journal of cancer vol. 95,1 (2006): 49-55. doi: https://doi.org/10.1038/sj.bjc.6603212
Uccini S, Colarossi C, Scarpino S, Boldrini R, Natali PG, Nicotra MR, Perla FM, Mannarino O, Altavista P, Boglino C, Cappelli CA, Cozzi D, Donfrancesco A, Kokai G, Losty PD, McDowell HP, Dominici C. Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours. Br J Cancer. 2006 Jul 03;95(1):49-55. doi: 10.1038/sj.bjc.6603212. Epub 2006 Jun 06. PMID: 16755292; PMCID: PMC2360487.
Copy Download .nbib Format: NLM
Share it on

Br J Cancer. 2006 Jul 03;95(1):49-55. doi: 10.1038/sj.bjc.6603212. Epub 2006 Jun 06.

Morphological and molecular assessment of apoptotic mechanisms in peripheral neuroblastic tumours.

British journal of cancer

S Uccini, C Colarossi, S Scarpino, R Boldrini, P G Natali, M R Nicotra, F M Perla, O Mannarino, P Altavista, C Boglino, C A Cappelli, D Cozzi, A Donfrancesco, G Kokai, P D Losty, H P McDowell, C Dominici

Affiliations

  1. Department of Experimental Medicine & Pathology, La Sapienza University, Viale Regina Elena 324, Rome I-00161, Italy. [email protected]

PMID: 16755292 PMCID: PMC2360487 DOI: 10.1038/sj.bjc.6603212

Abstract

Multiple defects in apoptotic pathways have been described in peripheral neuroblastic tumours (NTs). Mitosis-karyorrhexis index (MKI) is a reliable morphological marker identifying favourable and unfavourable NTs. The extent to which apoptotic processes contribute to determine the clinical significance of MKI is still undefined. Apoptosis was investigated in a series of 110 peripheral NTs by comparing MKI to immunohistochemical and molecular apoptotic features. High MKI was found in 55 out of 110 NTs (50%) and was associated with advanced stage (P = 0.007), neuroblastoma (NB) histological category (P = 0.024), MYCN amplification (P < 0.001), and poor outcome (P = 0.011). Overall survival probability was 45% in patients with high MKI compared to 73% in patients with low MKI. In the same 110 NTs, the expression of Bcl-2, Bcl-XL, Bax and Mcl-1 was studied by immunohistochemistry, but no significant associations were found with clinicohistological features. Microarray analysis of apoptotic genes was performed in 40 out of 110 representative tumours. No significant association was found between the expression of apoptotic genes and MKI or clinicohistological features. Proliferative activity was assessed in 60 out of 110 representative tumours using Ki67 immunostaining, but no significant correlations with MKI or clinicobiological features were found. In NTs, the combination of apoptosis and proliferation as expressed by MKI is a significant prognostic parameter, although neither of them is per se indicative of the clinicobiological behaviour and outcome.

References

  1. Cancer Res. 2002 Apr 1;62(7):2157-61 - PubMed
  2. Cancer. 2002 Mar 1;94(5):1574-83 - PubMed
  3. Cell. 2003 Jan 10;112(1):29-40 - PubMed
  4. Nat Rev Cancer. 2003 Mar;3(3):203-16 - PubMed
  5. Semin Cancer Biol. 2003 Apr;13(2):135-47 - PubMed
  6. J Clin Oncol. 2003 Apr 15;21(8):1592-601 - PubMed
  7. Cancer Lett. 2003 Jul 18;197(1-2):93-8 - PubMed
  8. Cancer Lett. 2003 Jul 18;197(1-2):131-5 - PubMed
  9. Cancer Res. 2003 Aug 1;63(15):4538-46 - PubMed
  10. Oncogene. 2003 Aug 21;22(35):5525-36 - PubMed
  11. Cancer Lett. 2004 Feb 20;204(2):213-24 - PubMed
  12. Ann N Y Acad Sci. 2003 Dec;1010:195-9 - PubMed
  13. Natl Cancer Inst Monogr. 1976 Nov;44:49-54 - PubMed
  14. Clin Exp Metastasis. 1989 Mar-Apr;7(2):201-11 - PubMed
  15. J Clin Oncol. 1993 Aug;11(8):1466-77 - PubMed
  16. Cancer Res. 1993 Nov 1;53(21):5269-73 - PubMed
  17. Am J Pathol. 1993 Dec;143(6):1543-50 - PubMed
  18. Cancer Res. 1994 Jun 15;54(12):3253-9 - PubMed
  19. Am J Pathol. 1995 Jan;146(1):3-15 - PubMed
  20. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4407-11 - PubMed
  21. Cancer Lett. 1995 May 8;91(2):161-8 - PubMed
  22. Cancer Res. 1995 Jun 15;55(12):2576-82 - PubMed
  23. J Pediatr Surg. 1995 Jun;30(6):805-8 - PubMed
  24. J Natl Cancer Inst. 1995 Oct 4;87(19):1470-6 - PubMed
  25. Eur J Cancer. 1995;31A(4):458-63 - PubMed
  26. Nat Genet. 1997 Oct;17(2):141-3 - PubMed
  27. Science. 1998 Aug 28;281(5381):1312-6 - PubMed
  28. Science. 1998 Aug 28;281(5381):1317-22 - PubMed
  29. Curr Opin Cell Biol. 1999 Apr;11(2):255-60 - PubMed
  30. J Pathol. 1999 Jan;187(1):112-26 - PubMed
  31. Cancer. 1999 Jul 15;86(2):349-63 - PubMed
  32. Cancer. 1999 Jul 15;86(2):364-72 - PubMed
  33. Nature. 2006 Jan 5;439(7072):95-9 - PubMed
  34. Nat Med. 2000 May;6(5):529-35 - PubMed
  35. Cancer Res. 2000 Aug 15;60(16):4315-9 - PubMed
  36. Cancer Lett. 2001 Aug 28;169(2):107-14 - PubMed
  37. Cancer. 2001 Nov 1;92(9):2451-61 - PubMed
  38. Nat Rev Cancer. 2002 Sep;2(9):647-56 - PubMed

Substances

MeSH terms

Publication Types